CD274 and esophageal adenocarcinoma: In summary, it means that regardless of PD-L1 CPS expression level, nivolumab plus chemotherapy regimen as first-line treatment of advanced GC/GEJC/esophageal adenocarcinoma is not cost-effective in China, despite having a greater survival benefit as evaluated by QALYs.